We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Key study details
Objective
To test whether daily β-1,3/1,6-D-glucan from Ganoderma lucidum (Reishi) modulates immune cell profiles in healthy adults, and to evaluate safety over 12 weeks.
Methods
- Randomized, double-blind, placebo-controlled trial in healthy adults (18–55 y).
- Participants were assigned to 200 mg/day Reishi β-glucan capsules or 200 mg dextrose placebo for 84 days.
- Primary endpoints (baseline and week 12): total lymphocytes, CD3⁺, CD4⁺, CD8⁺ T-cell counts, CD4/CD8 ratio, NK-cell counts, and NK cytotoxicity.
- Secondary endpoints: safety labs (AST, ALT, creatinine, CBC indices).
- 157 randomized; 135 completed (Reishi n=70; placebo n=65).
Results
- Compared with placebo at week 12, the Reishi group showed higher lymphocyte and T-cell counts (CD3⁺, CD4⁺, CD8⁺), higher CD4/CD8 ratio, higher NK-cell counts, and markedly higher NK cytotoxicity; serum IgA also increased.
- Liver and kidney function tests and hematologic indices showed no significant between-group differences.
Our take
Interpretation
Daily 200 mg Reishi β-glucan for 12 weeks produced coordinated increases in innate (NK) and adaptive (T-cell) markers in healthy adults without laboratory safety signals. The trial supports systemic immunomodulation, but it did not measure gut endpoints (microbiome, SCFAs, barrier markers), so any gut-mediated contribution is undetermined here.
Mechanisms & pathways discussed
The manuscript frames fungal β-glucans as PRR ligands (e.g., Dectin-1, CR3, TLRs), which can trigger downstream immune signaling; however, mechanistic assays were not performed in this RCT (no receptor, cytokine-pathway, or gut-microbiome readouts in participants).
Dosages & adverse reactions
- Dose/Regimen: 200 mg β-glucan/day (single capsule) for 84 days; placebo was 200 mg dextrose.
- Safety/Tolerability: No adverse events noted, AST/ALT/creatinine unchanged vs placebo at week 12.
Quality of study (assessment)
- Strengths: Prospective RCT, double-blind design; prespecified cellular immune endpoints; adequate treatment duration (12 weeks); dose specified; DSMB oversight; direct reporting of safety labs.
- Limitations: Healthy volunteer population (no clinical infection outcomes); no gut-specific measures; immune endpoints are laboratory markers (surrogates); manufacturer-specific extract and sponsor involvement may limit generalizability.
Implications
For immuno-nutrition in healthy adults, Reishi β-glucan 200 mg/day can enhance NK/T-cell indices without short-term lab safety concerns. Clinically meaningful outcomes (e.g., infection incidence/severity) and gut-focused effects require trials that include microbiome/SCFA/barrier readouts and standardized β-glucan characterization.
This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.
Citation
Copied!